WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Apellis is exclusively distributing injection kits with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback